Contralateral breast cancer risk in patients with ductal carcinoma in situ and invasive breast cancer

Daniele Giardiello, Iris Kramer, Maartje J. Hooning, Michael Hauptmann, E. Lips, Elinor Sawyer, Alastair M. Thompson, Linda de Munck, Sabine Siesling, Jelle Wesseling, Ewout W. Steyerberg, Marjanka K. Schmidt

Research output: Contribution to journalArticleAcademicpeer-review

16 Downloads (Pure)

Abstract

We aimed to assess contralateral breast cancer (CBC) risk in patients with ductal carcinoma in situ (DCIS) compared with invasive breast cancer (BC). Women diagnosed with DCIS (N = 28,003) or stage I–III BC (N = 275,836) between 1989 and 2017 were identified from the nationwide Netherlands Cancer Registry. Cumulative incidences were estimated, accounting for competing risks, and hazard ratios (HRs) for metachronous invasive CBC. To evaluate effects of adjuvant systemic therapy and screening, separate analyses were performed for stage I BC without adjuvant systemic therapy and by mode of first BC detection. Multivariable models including clinico-pathological and treatment data were created to assess CBC risk prediction performance in DCIS patients. The 10-year cumulative incidence of invasive CBC was 4.8% for DCIS patients (CBC = 1334). Invasive CBC risk was higher in DCIS patients compared with invasive BC overall (HR = 1.10, 95% confidence interval (CI) = 1.04–1.17), and lower compared with stage I BC without adjuvant systemic therapy (HR = 0.87; 95% CI = 0.82–0.92). In patients diagnosed ≥2011, the HR for invasive CBC was 1.38 (95% CI = 1.35–1.68) after screen-detected DCIS compared with screen-detected invasive BC, and was 2.14 (95% CI = 1.46–3.13) when not screen-detected. The C-index was 0.52 (95% CI = 0.50–0.54) for invasive CBC prediction in DCIS patients. In conclusion, CBC risks are low overall. DCIS patients had a slightly higher risk of invasive CBC compared with invasive BC, likely explained by the risk-reducing effect of (neo)adjuvant systemic therapy among BC patients. For support of clinical decision making more information is needed to differentiate CBC risks among DCIS patients.
Original languageEnglish
Article number60
Journalnpj Breast Cancer
Volume6
Early online date3 Nov 2020
DOIs
Publication statusPublished - 2020

Fingerprint

Dive into the research topics of 'Contralateral breast cancer risk in patients with ductal carcinoma in situ and invasive breast cancer'. Together they form a unique fingerprint.

Cite this